Quick Answer
Atea Pharmaceuticals, Inc. reported Net Income Loss of -$158.35 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +6.0% in Net Income Loss from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$2.19 million | Q2 2019: -$3.55 million | Q3 2019: -$3.63 million | Q1 2020: -$3.99 million | Q2 2020: -$9.99 million | Q3 2020: -$17.62 million | Q1 2021: $30.71 million | Q2 2021: $1.54 million | Q3 2021: -$28.19 million | Q1 2022: -$42.08 million | Q2 2022: -$31.34 million | Q3 2022: -$8.07 million | Q1 2023: -$35.47 million | Q2 2023: -$28.18 million | Q3 2023: -$33.14 million | Q1 2024: -$63.17 million | Q2 2024: -$40.52 million | Q3 2024: -$31.15 million | Q1 2025: -$34.27 million | Q2 2025: -$37.16 million | Q3 2025: -$42.05 million.
- Over the full 8 years of available data (2018 to 2025), Atea Pharmaceuticals, Inc.'s Net Income Loss has declined by 1,647.0%.
- Historical annual values: Fiscal year 2025: -$158.35 million | Fiscal year 2024: -$168.39 million | Fiscal year 2023: -$135.96 million | Fiscal year 2022: -$115.91 million | Fiscal year 2021: $121.19 million | Fiscal year 2020: -$10.95 million | Fiscal year 2019: -$14.03 million | Fiscal year 2018: -$9.06 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: